Assessment of Glycolysis/OXPHOS as ATP related cancer metabolism and overcoming of drug resistance in lung adenocarcinoma

2019 Fiscal Year Final Research Report

• Project/Area Number: 19K21338
• Project/Area Number (Other): 18H06242 (2018)
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund (2019); Single-year Grants (2018)
• Review Section: 0905:Surgery of the organs maintaining homeostasis and related fields
• Research Institution: Hiroshima University
• Principal Investigator: Mimae Takahiro 広島大学, 病院(医), 助教 (00634081)
• Project Period (FY): 2018-08-24 – 2020-03-31
• Keywords: 肺腺癌 / がん代謝 / 酸化的リン酸化 / Glycolysis

Outline of Final Research Achievements

To identify the novel target and development for therapy of lung adenocarcinoma, we identified the several pathways of dominant cancer metabolisms of lung adenocarcinoma and disclose that inhibitor targeting that cancer metabolism repressed the cell growth of lung adenocarcinoma in vitro. To investigate if the inhibitor is also effective in human, we examined TCGA (The Cancer Genome Atlas) database and found that human lung adenocarcinomas were classified based on the dominant cancer metabolism types. In addition, we are now trying to conduct human lung adenocarcinoma samples to immunohistochemistry targeting the representative molecules of the identified cancer metabolism. That results will provide useful information continuing to clinical application.

Free Research Field

呼吸器外科

Academic Significance and Societal Importance of the Research Achievements

肺癌は未だ克服されていない病気であり、肺腺癌はその代表的な組織型の１つである。
本研究の結果は、その新規治療標的の同定および新規治療開発に関してがん代謝が非常に有望であることに加えて、実際に使用可能な拮抗薬の同定、ヒトへの応用の可能性の示唆にも至っている。動物実験や第1相臨床試験を経る必要はあるが、今後の臨床応用が期待される。また、がん代謝を標的とした治療はまだまだ確立されたものがないため新規性もある。